Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

September 25, 2021 by Alan Khadavi

Opzelura (ruxolitinib) for Eczema

Opzelura (ruxolitinib) has been FDA approved for eczema. Opzelura is a topical JAK inhibitor, and its indicated for short term use in patients 12 and up who have mild to moderate atopic dermatitis. It is the first topical janus kinase inhibitor approved in the United States.

Currently for atopic dermatitis topical treatment, the mainstay of treatment are topical corticosteroids, such as hydrocortisone, triamcinolone and there are many to choose from. Elidel/Protopic were the next topical treatments approved, followed by Eucrisa. Opzelura is the first topical therapy in its class to be approved for eczema.

We have discussed extensively in the past JAK inhibitors for atopic dermatitis, but most of them are being studied in the oral form.

Abrocitinib for Atopic Dermatitis by Pfizer

Upadacitinib for Atopic Dermatitis (Eczema)

JAK inhibitors block an inflammatory pathway that lead to different immune responses. JAK inhibitors are currently used inflammatory diseases such as rheumatoid arthritis and treatments of cancer.

The approval of Ruxolitinib was based on 2 phase 3 studies involving more than 1200 patients with mild to moderate eczema. Approximately 52% of patients receiving Ruxolitinib reached the primary endpoint of treatment goals after 8 weeks.

The most common adverse events were nasopharyngitis, diarrhea, bronchitis and ear infections. Although more adverse events can be reported once the medication is used in a broader population.

With other oral JAK inhibitors on the way, it remains to be seen which treatment would be better in the topical vs. the oral route of these medications.

Most new medications like Opzelura are significantly expensive when they are first released on the market. But the manufacturer, in this case Incyte Dermatology, provides coupons or discounts to patients when the drug is not covered by insurance companies.

Stay tuned for more information, Ruxolitinib cream is also being evaluated for the treatment of vitiligo. To read more, please click on the link below regarding a blog that was written about it last year.

Ruxolitinib for Eczema (atopic dermatitis)

Atopic Dermatitis (Eczema) Treatment

Treatment of Atopic Dermatitis (Eczema)

 

 

Filed Under: atopic dermatitis, Blog, Medications

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

March 16, 2023

Does an Air Purifier help Asthma?

air purifier help asthma

March 13, 2023

Tezspire vs. Nucala vs. Fasenra vs. Dupixent for Eosinophilic Asthma, a comparison

Tezspire vs. Nucala vs. Fasenra vs. Dupixent

February 16, 2023

Cucumber Allergy can come in many flavors

cucumber allergy

February 10, 2023

Do Allergy Shots help Eczema?

Can allergy shots help eczema?

January 22, 2023

Is Benadryl Safe to use, or is it Time to Move on?

is benadryl safe

January 12, 2023

Airsupra for Asthma, a new rescue medication

airsupra

December 26, 2022

Cantaloupe Allergy comes in many flavors

cantaloupe allergy

December 23, 2022

Remibrutinib, a BTK inhibitor for Chronic Hives

remibrutininb

November 21, 2022

Eczema and Hard Water, is there a link?

eczema and hard water

November 19, 2022

Nucala, Fasenra or Dupixent for Severe Eosinophilic Asthma?

nucala fasenra dupixent

Read More Posts...

Follow Us…

© 2023 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page